Dyslipidaemia is a well-established risk factor for CVD and statins have proven benefits in CVD risk reduction. However, they are not without side effects and lipid-lowering drugs cost the PBS over $1 billion in 2014-15, more than any other class of medication. One of the major challenges for GP registrars moving from the hospital environment into general practice is the management of chronic disease, including risk factor modification. Management of dyslipidaemia as part of absolute CVD risk is a new area of practice for many registrars.